Additionally, in tumor immunotherapy, IL-12 therapy induces Th1 cell differentiation [62], increases the infiltration of NK and CD8+ T cells to tumor sites [63] and triggers an anti-angiogenic program to exert anti-tumor activity [64, 65]. The gene discussed is CD8A; the disease is neoplasm.